|
|
|
| Effects of Liraglutide and Empagliflflozin Added to Insulin Therapy in Patients With Type 2 Diabetes：A Randomized Controlled Study |
| Zheng Yu |
| Shangqiu Central Hospital of Henan Province, Shangqiu 476000, China |
|
|
|
|
Abstract Objective To investigate the clinical efficacy of liraglutide and empagliflozin combined with insulin in the treatment of type 2 diabetes. Methods A total of 180 patients with type 2 diabetes who were treated in our hospital were selected and divided into observation group（90 cases）and control group（90 cases）according to the double-blind method.The observation group was treated with liraglutide combined with insulin,and the control group was treated with empagliflozin combined with insulin.Participants received 0.9 mg/d liraglutide or 10 mg/d epagliflozin for 24 weeks.The HbA1c（glycated hemoglobin）,GA（glycated albumin）,and PPG（postprandial plasma glucose）of the two groups after 24 weeks of treatment were compared. Results The HbA1c（glycated hemoglobin）（6.80±0.14）% of the observation group after 24 weeks of treatment was less than the HbA1c（glycated hemoglobin）（7.73±0.83）% of the control group after 24 weeks of treatment.The difference was statistically significant（P<0.05）.GA（glycated albumin）（18.32±0.42）% after 24 weeks of treatment was less than that of the control group after 24 weeks of treatment（19.49±0.29）%,the difference was statistically significant（P<0.05）,the observation group was treated After 24 weeks,PPG（postprandial plasma glucose）（159.01±8.89）% was less than that of the control group after 24 weeks of treatment（172.16±10.64）%,the difference was statistically significant（P<0.05）. Conclusion In patients with inadequate control of type 2 diabetes,in addition to ongoing insulin therapy,liraglutide is more effective than empagliflozin in reducing the levels of glycosylated hemoglobin and glycosylated albumin,which is worthy of clinical promotion.
|
|
Received: 11 August 2021
|
|
|
|
|
|
[1] 崔克勤,王海燕,唐键,等.利拉鲁肽单药治疗新诊超重或肥胖2型糖尿病的效果及安全性观察[J].山东医药,2016,56(30):47-49.
[2] 王建中. Semaglutide降低2型糖尿病患者的心脑血管事件风险[J].中华肾病研究电子杂志,2016,32(5):24-56.
[3] 德鲁克等. 肠促胰岛素激素的生物学[J].细胞代,2016,13(3):153-165.
[4] 田勍,洪天配.基础胰岛素与胰高血糖素样肽-1受体激动剂联合治疗糖尿病的合理性[J].中国糖尿病杂志,2012,4(8):500-502.
[5] 沈和荣. 格列美脲联合治疗单用胰岛素效果不佳2型糖尿病患者的临床观察[J].医药论坛杂志,2013,54(11):19-20.
[6] 钱荣立. 解读美国糖尿病学会与欧洲糖尿病研究协会关于“以患者为中心的2型糖尿病高血糖管理方案”的立场声明[J].中国糖尿病杂志,2013,21(1):5-6.
[7] 朱振航,陈凤玲.GLP-1RA在糖尿病神经病变治疗中潜在作用及机制研究进展[J].医学综述,2017,56(10):12-457.
[8] Seino Y,Kaneko S,Fukuda S,et al:Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes:a 36-week,randomized,double-blind,parallel-group trial[J].Diabetes Investig,2016,15(7):565-573.
[9] 陶晓明、蒋翠萍、黄宇新,等.二甲双胍联合磺脲类降糖药或二肽基肽酶4抑制剂在全面血糖控制上的差异[J].中国临床药学杂志,2020,29(6):31-35.
[10] 范莉萍,孙丽,朱志良.沙格列汀及二甲双胍联合应用对非肥胖2型糖尿病患者体重及体脂变化的影响[J].中国保健营养,2019,29(23):31-32.
[11] Araki E,Onishi Y,Asano M,et al.Efficacy and safety of dapagliflozin over 1 year as add-on to insulin therapy in Japanese patients with type 2 diabetes:the DAISY(Dapagliflozin Added to patients under InSulin therapY)trial[J].Diabetes Obes Metab,2017,16(19):562-570.
[12] 周洋,石秀锦,彭文星等.2014-2018年我国七城市二肽基肽酶Ⅳ抑制剂和胰高血糖素样肽1受体激动剂及钠-葡萄糖共转运蛋白2抑制剂使用情况调查[J].中国医药,2020,15(1):130-134.
[13] Mann JFE,rsted DD,Brown-Frandsen K,et al.Liraglutide and renal outcomes in type 2 diabetes.N Engl[J].Med,2017,11(377):839-848.
[14] 赵凡,丁国华.2型糖尿病肾病患者肾血流阻力指数与血清脂蛋白a对肾功能进展的预测[J].医学研究杂志,2019,13(11):24-30. |
| [1] |
. [J]. journal1, 2022, 42(5): 120-121. |
| [2] |
. [J]. journal1, 2022, 42(3): 56-57. |
| [3] |
. [J]. journal1, 2022, 42(3): 62-63. |
| [4] |
. [J]. journal1, 2022, 42(3): 129-130. |
| [5] |
. [J]. journal1, 2022, 42(2): 78-79. |
| [6] |
. [J]. journal1, 2021, 41(6): 73-74. |
|
|
|
|
2022, Vol. 42 
